|
|
 Previous Article | Table of Contents | Next Article 
In vivo stimulation of megakaryocytopoiesis by recombinant murine
granulocyte-macrophage colony-stimulating factor
AM Vannucchi, A Grossi, D Rafanelli and PR Ferrini
Division of Hematology, University of Florence-USL 10/D, Italy.
Murine recombinant granulocyte-macrophage colony-stimulating factor
(rGM-CSF) was injected in mice, and the effects on bone marrow, splenic
megakaryocytes, megakaryocyte precursors (megakaryocyte colony-forming
units [CFU-Meg]) were evaluated. In mice injected three times a day for 6
days with 12,000 to 120,000 U rGM-CSF, no significant modification of both
platelet levels and mean platelet volume was observed, while there was a
twofold increase in blood neutrophils. However, the rate of platelet
production, as assessed by the measurement of 75selenomethionine
incorporation into blood platelets, was On the contrary, administration of
up to 384,000 U rGM-CSF two times a day for 2 days, as for a typical
"thrombopoietin assay," failed to modify platelet production. A significant
dose-related increase in the number of splenic megakaryocytes occurred in
mice receiving 60,000 to 120,000 U rGM-CSF, while a slight increase in the
number of bone marrow megakaryocytes was observed in mice injected with
120,000 U rGM-CSF. The proportion of bone marrow megakaryocytes with a size
less than 18 microns and greater than 35 microns resulted significantly
higher in mice receiving rGM-CSF in comparison with controls; an increase
in the percentage of splenic megakaryocytes greater than 35 microns was
also observed. A statistically significant increase in the total spleen
content of CFU-Meg was observed after administration of 90,000 and 120,000
U rGM-CSF three times a day for 6 days, while no effect on bone marrow
CFU-Meg was recorded, irrespective of the dose delivered. Finally, 24 hours
after a single intravenous injection of rGM-CSF, there was a significant
increase in the proportion of CFU-Meg in S- phase, with the splenic
progenitors being more sensitive than bone marrow-derived CFU-Meg. These
data indicate that rGM-CSF has in vivo megakaryocyte stimulatory activity,
and are consistent with previous in vitro observations. However, an
effective stimulation of megakaryocytopoiesis in vivo, bringing about an
increase in the levels of blood platelets, may require interaction of
rGM-CSF with other cytokines.
Volume 76,
Issue 8,
pp. 1473-1480,
10/15/1990
Copyright © 1990 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
T. Yamao, T. Noguchi, O. Takeuchi, U. Nishiyama, H. Morita, T. Hagiwara, H. Akahori, T. Kato, K. Inagaki, H. Okazawa, et al.
Negative Regulation of Platelet Clearance and of the Macrophage Phagocytic Response by the Transmembrane Glycoprotein SHPS-1
J. Biol. Chem.,
October 11, 2002;
277(42):
39833 - 39839.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Cardier, C. L. Erickson-Miller, and M. J. Murphy Jr.
Differential Effect of Erythropoietin and GM-CSF on Megakaryocytopoiesis from Primitive Bone Marrow Cells in Serum-Free Conditions
Stem Cells,
July 1, 1997;
15(4):
286 - 290.
[Abstract]
[Full Text]
|
|
|
|
|
